Abstract
I-123 15-(p-iodophenyl)-3-(R,S)-methylpentadecanoic acid (BMIPP) was introduced as an approved radiopharmaceutical in Japan in 1993. This article reviews our clinical comparisons between BMIPP and PET metabolism conducted at Kyoto University. BMIPP uptake was suggested to reflect exogenous fatty acid utilization in the myocardium. By the comparison between FDG PET and BMIPP SPECT, reduced uptake of BMIPP relative to thallium was considered metabolically damaged but viable myocardium in ischemic coronary artery disease. In hypertrophic cardiomyopathy, reduction of BMIPP uptake was shown to precede suppression of oxidative or glucose metabolism. Occasionally we encounter subjects with absent myocardial BMIPP uptake. The majority of these subjects showed metabolic switching from normal free fatty acid metabolism to abnormally enhanced glucose metabolism in the fasting state. Thus, BMIPP provides us with the valuable metabolic information which is unattainable using a perfusion tracer.
Similar content being viewed by others
References
Schelbert HR. Positron emission tomography. Diagnostic and therapeutic implications in human myocardial ischemia. Int J Card Imaging 1987; 2: 199-208.
Bax JJ, Visser FC, van Lingen A, Cornel JH, Fioretti PM, van der Wall EE. Metabolic imaging using F18-fluorodeoxyglucose to assess myocardial viability. Int J Card Imaging 1997; 13: 145-155.
Schwaiger M, Schelbert HR, Keen R, Vinten-Johansen J, Hansen H, Selin C, et al. Retention and clearance of C-11 palmitic acid in ischemic and reperfused canine myocardium. J Am Coll Cardiol 1985 Aug; 6(2): 311-320.
Walsh MN, Geltman EM, Brown MA, Henes CG, Weinheimer CJ, Sobel BE, et al. Noninvasive estimation of regional myocardial oxygen consumption by positron emission tomography with carbon-11 acetate in patients with myocardial infarction. J Nucl Med 1989; 30: 1798-1808.
Armbrecht JJ, Buxton DB, Schelbert HR. Validation of [1–11C]acetate as a tracer for noninvasive assessment of oxidative metabolism with positron emission tomography in normal, ischemic, postischemic, and hyperemic canine myocardium. Circulation 1990; 81: 1594-1605.
Beanlands RS, Bach DS, Raylman R, Armstrong WF, Wilson V, Montieth M, et al. Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-11 acetate kinetics in patients with dilated cardiomyopathy. J Am Coll Cardiol 1993; 22: 1389-1398.
Hata T, Nohara R, Fujita M, Hosokawa R, Lee L, Kudo T et al. Noninvasive assessment of myocardial viability by positron emission tomography with C-11 acetate in patients with old myocardial infarction. Usefulness of low-dose dobutamine infusion. Circulation 1996; 94: 1834-1841.
Marhsall RC, Tillisch JH, Phelps ME, Huang SC, Carson R, Henze E, et al. Identification and differentiation of resting myocardial ischemia and infarction in man with positron computed tomography, 18F-labeled fluorodeoxyglucose and N-13 ammonia. Circulation 1983; 67: 766-778.
Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986; 314: 884-888.
Tamaki N, Ohtani H, Yamashita K, Magata Y, Yonekura Y, Nohara R, et al. Metabolic activity in the areas of new fill-in after thallium-201 reinjection: comparison with positron emission tomography using fluorine-18-deoxyglucose. J Nucl Med 1991; 32: 673-678.
Knuuti MJ, Nuutila P, Ruotsalainen U, Saraste M, Harkonen R, Ahonen A, et al. Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography. J Nucl Med 1992; 33: 1255-1262.
Tamaki N, Kawamoto M, Tadamura E, Magata Y, Yonekura Y, Nohara R, et al. Prediction of reversible ischemia after revascularization. Perfusion and metabolic studies with positron emission tomography. Circulation 1995; 91: 1697-1705.
Iida H, Rhodes CG, Araujo LI, Yamamoto Y, de Silva R, Maseri A, et al. Noninvasive quantification of regional myocardial metabolic rate for oxygen by use of 15O2 inhalation and positron emission tomography. Theory, error analysis, and application in humans, Circulation 1996 15; 94: 792-807.
Knapp FF Jr, Goodman MM, Callahan AP, Kirsch G. Radioiodinated 15-(p-iodophenyl)-3,3-dimethylpentadecanoic acid: a useful new agent to evaluate myocardial fatty acid uptake. J Nucl Med 1986; 27: 521-531.
Knapp FF, Franken P, Kropp J. Cardiac SPECT with iodine-123-labeled fatty acids: evaluation of myocardial viability with BMIPP. J Nucl Med 1995; 36: 1022-1030.
Tamaki N, Kawamoto M, Yonekura Y, Fujibayashi Y, Takahashi N, Konishi J, et al. Regional metabolic abnormality in relation to perfusion and wall motion in patients with myocardial infarction: assessment with emission tomography using an iodinated branched fatty acid analog. J Nucl Med 1992; 33: 659-667.
Tateno M, Tamaki N, Yukihiro M, Kudoh T, Hattori N, Tadamura E, et al. Assessment of fatty acid uptake in ischemic heart disease without myocardial infarction. J Nucl Med 1996; 37: 1981-1985.
Takeishi Y, Fujiwara S, Atsumi H, Takahashi K, Sukekawa H, Tomoike H. Iodine-123-BMIPP imaging in unstable angina: a guide for interventional strategy. J Nucl Med 1997; 38: 1407-1411.
Kurata C, Tawarahara K, Taguchi T, Aoshima S, Kobayashi A, Yamazaki N, et al. Myocardial emission computed tomography with iodine-123-labeled beta-methyl-branched fatty acid in patients with hypertrophic cardiomyopathy. J Nucl Med 1992; 33: 6-13.
Takeishi Y, Chiba J, Abe S, Tonooka I, Komatani A, Tomoike H. Heterogenous myocardial distribution of iodine-123 15-(p-iodophenyl)-3-R,S-methylpentadecanoicacid (BMIPP) in patients with hypertrophic cardiomyopathy. Eur J Nucl Med 1992; 29: 775-782.
Kawamoto M, Tamaki N, Yonekura Y, Magata Y, Tadamura E, Nohara R, et al. Significance of myocardial uptake of iodine 123-labeled beta-methyl iodophenyl pentadecanoic acid: comparison with kinetics of carbon 11-labeled palmitate in positron emission tomography. J Nucl Cardiol 1994; 1: 522-528.
Kawamoto M, Tamaki N, Yonekura Y, Tadamura E, Fujibayashi Y, Magata Y, et al. Combined study with I-123 fatty acid and thallium-201 to assess ischemic myocardium: comparison with thallium redistribution and glucose metabolism. Ann Nucl Med 1994; 8: 47-54.
Tamaki N, Tadamura E, Kawamoto M, Magata Y, Yonekura Y, Fujibayashi Y, et al. Decreased uptake of iodinated branched fatty acid analog indicates metabolic alterations in ischemic myocardium. J Nucl Med 1995; 36: 1974-1980.
Kudoh T, Tamaki N, Magata Y, Konishi J, Nohara R, Iwasaki A, et al. Metabolism substrate with negative myocardial uptake of iodine-123-BMIPP. J Nucl Med 1997; 38: 548-553.
Tadamura E, Tamaki N, Matsumori A, Magata Y, Yonekura Y, Nohara R, et al. Myocardial metabolic changes in hypertrophic cardiomyopathy. J Nucl Med 1996; 37: 572-577.
Ishiwata S, Maruno H, Senda M, Toyama H, Nishiyama S, Seki A. Myocardial blood flow and metabolism in patients with hypertrophic cardiomyopathy — a study with carbon-11 acetate and positron emission tomography. Jpn Circ J 1997; 61: 201-210.
Tadamura E, Kudoh T, Hattori N, Inubushi M, Magata Y, Konishi J, et al. Impairment of BMIPP uptake precedes abnormalities in oxygen and glucose metabolism in hypertrophic cardomyopathy. J Nucl Med 1998; 39: 390-396.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tadamura, E., Tamaki, N., Kudoh, T. et al. BMIPP compared with PET metabolism. Int J Cardiovasc Imaging 15, 61–69 (1999). https://doi.org/10.1023/A:1006148619691
Issue Date:
DOI: https://doi.org/10.1023/A:1006148619691